Pear Therapeutics to Become Public Via THMA SPAC Merger for ~$1.6B
Shots:
- Pear signs a SPAC merger with THMA for pro forma equity value of ~ $1.6B & is expected to provide ~ $400M in gross proceeds include $276M in Thimble Point’s trust account & $125M upsized PIPE at $10.00/ share. The combined company is expected to have ~$450M in net cash & transaction is expected to end in H2’21
- The combination will provide additional investment to capitalize Pear’s leading position by investing in the commercialization of Pear’s 3 FDA-authorized products- advance Pear’s pipeline & scaling its platform to host PDTs
- Pear equity holders will hold ~72% outstanding equity of combined company while Pear expect to be trade on Nasdaq under the ticker “PEAR”
| Ref: Business Wire | Image: Business Wire
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com